Aug. 5, 2013
/PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) drug development pathway, today announced CEO
Mark L. Baum
will present at the Southern California Investor Conference on
August 8, 2013
at the Island Hotel in
Newport Beach, CA.
The Imprimis presentation is scheduled to begin at
11 a.m. ET
8 a.m. PT
. in Room 2.
About Imprimis Pharmaceuticals, Inc
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) is a specialty pharmaceutical company focused on the commercial development of drug formulations utilizing the FDA 505(b)(2) drug development pathway. Through its exclusive strategic relationship with the largest compounding pharmacy organization in
as well as through a growing network of commercial development relationships with pharmacists and physicians across
the United States
, Imprimis expects to use proprietary drug delivery technologies, proven drug formulations and proprietary market data to identify and pursue pharmaceutical development opportunities where there is a significant unmet medical need. Imprimis' most near term drug candidate, Impracor, is a Phase III product candidate that utilizes its patented Accudel topical cream formulation to deliver the active drug ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. For more information, visit
Imprimis Pharmaceuticals, Inc.(858) 704 4041
SOURCE Imprimis Pharmaceuticals, Inc.